New treatments are continually being developed for women with ovarian cancer. Keep up to date with the latest news!

Platinum based chemo should not be delayed for recurrent OC

Most patients treated for ovarian cancer experience progression after surgery and first-line platinum-based chemotherapy. Subsequent treatment with platinum-based chemotherapy among patients with progressing ovarian cancer may be more effective with a longer interval from previous platinum treatment.

Learn more about the research that led to this discovery

Researchers may be closer to a test for ovarian cancer!

Researchers from Dana-Farber Cancer Institute and Brigham and Women’s Hospital, both in Boston, created a technique to detect ovarian cancer early and accurately.

Learn more!

Avastin + Carboplatin + Taxol = First Line Treatment!

Genentech recently announced that the FDA has accepted the supplemental biologics application (sBLA) for bevacizumab (Avastin) plus carboplatin and paclitaxel chemotherapy followed by bevacizumab as a first-line therapy for patients with advanced ovarian cancer.

Clinical trials showed that this combination therapy offered benefits to patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Read Genentech's press release

White Blood Cells Found in High Grade Ovarian Cancer May Point to Survival Outcomes

An international, large scale study may have found a link between high-grade ovarian cancer and a type of white blood cell known as a tumor-
Recently published in *JAMA Oncology*, the article from the Ovarian Tumor Tissue Analysis Consortium discussed the study, which involved about 5,500 patients, 3,196 of whom had high-grade ovarian cancer.

Although it was previously established that high grade ovarian cancer tumors contain cytotoxic CD8, a type of tumor infiltrating lymphocyte, the study found a direct correlation between the levels of CD8 and survival: the higher the CD8 level, the better the survival for patients.

*Follow this link for more information*

---

**Dynamic Duo attack Ovarian Cancer**

Bristol-Myers will line up its PD-1 immuno-therapy alongside Clovis’ PARP inhibitor Rubraca in two pivotal late-stage trials, one in ovarian cancer and the other in triple-negative breast cancer. In both cases, the drugs would be used as maintenance therapy, to ward off a cancer recurrence.

*Learn about this clinical trial*

---

**Grant for developing Immunotherapy Treatment for ovarian cancer**

Researchers at the University of California San Diego School of Medicine have received a $5.8 million state grant to develop an immunotherapy against hard-to-kill cancer stem cells.

The team that won the 30-month grant from the California Institute for Regenerative Medicine hopes to develop a treatment that uses patients’ own cells to target cancer stem cells. The effort has implications for ovarian cancer, among others.

*You can find out more in this article*
New Evidence Suggests OC Might Not Start in The Ovaries

A new study looking at how ovarian cancer starts has suggested it takes hold in the fallopian tubes, between the ovaries and the uterus, rather than in the ovaries themselves.

This discovery could transform the way we detect and treat this deadly disease. Ovarian cancer is notoriously hard to catch early and is usually well-developed by the time it's discovered - so catching it earlier could be crucial in saving lives.

Check out this research!

*Mutation in fallopian tube lesions may help catch ovarian cancer years earlier*